On September 15, 2022, the cooperative exchange meeting jointly organized by SUP and Henan DanJia Health Management was successfully held.

Mr. Zhao Weikai, General Manager, and Ms. Tian Lina, Marketing Director of Henan DanJia Health Management, attended the cooperative exchange meeting and introduced the company's development history and notable achievements. Founded in 2017, the company focuses on the promotion and marketing services of prescription drugs, adhering to the business philosophy of "Segmented Market, Maximum Share," leveraging its professional expertise to hold a leading position in the Henan pharmaceutical market.

Mr. Ding Pengcheng, Henan Regional Manager of SUP, provided a detailed introduction to the innovative positioning of SUP as a one-stop distribution management service provider. The attending guests highly praised SUP's corporate mission of "Import High-quality Medicines Globally to Serve Healthy China" and fully recognized the company's values of "Striving, Focus, Value, Win-win".

In general, for the first seven batches of national VBP, nearly 300 varieties have been included, with an average price reduction of around 50%. Many highly anticipated varieties have experienced significant price drops. With the close linkage between national and provincial procurement and the stable new norm, the comprehensive expansion of VBP, the survival and development of pharmaceutical enterprises have become urgent issues for many distributors. Mr. Xiao Chunchao, Central Region Manager of SUP Marketing Center, delivered a keynote speech titled New policy, new model, co-development and sharing of SUP Ecosystem to the attendees. He shared how SUP closely follows the new VBP policy, and has established a SUP ecosystem that includes product strategy consulting services, supply chain management services, multi-channel marketing services, and innovative customization services.

Lenalidomide, as a new generation immune modulator, is widely used in the treatment of diseases such as multiple myeloma, lymphoma, myelodysplastic syndromes, and acute myeloid leukemia. Ms. Sun Chaoyang from the Marketing Department of SUP delivered a presentation to the audience about 乐安吉瑞® Lenalidomide Capsules, imported in its original form by SUP, being first generic approved by the FDA.

乐安吉瑞^® Lenalidomide Capsules have been approved for indications related to multiple myeloma and follicular lymphoma, potentially benefiting a broader range of clinical patients.

As a leading player in the field of small molecule anti-tumor drugs, the continuous market demand has always been ignited. The high-quality and cost-effective products brought by SUP will bring greater benefits to Chinese patients.

Lenangio^® Prescription

[Drug Name] Lenalidomide Capsules

[Generic Name] Lenalidomide Capsules

[Description] The content of the product is white to a off-white powder

[Specifications] (1) 10mg (2) 25mg (for multiple myeloma only)

[Indications]

This product is combined with dexamethasone to treat previously untreated adult patients with multiple myeloma who are not suitable for transplantation.

This product is combined with dexamethasone to treat adult patients with multiple myeloma who have received at least one therapy.

This product is combined with rituximab in treating adult patients with previously treated follicular lymphoma (grade 1-3a).

[Dosage and Administration]

The treatment medication must be initiated and provided under the supervision of physicians with experience in multiple myeloma treatment, and the treatment must not be started if the absolute neutrophil count (ANC) is <1.0109 / L, and / or platelet count is <50109 / L.

Recommended dose: the recommended starting dose of this product is 25mg. On days 1 to 21 of each repeated 28-day cycle, 25mg product was orally administered daily until disease progression. The recommended dose of dexamethasone is oral 40mg of dexamethasone on days 1,8,15, and 22 of every 28-day treatment cycle. The prescriber should choose the starting dose and subsequent dose adjustment of dexamethasone according to the patient's age (see instructions for details).

[Storage] Sealed and stored at room temperature (10~30℃)

[Shelf life] 36 months

[Manufacturer] Dr. Reddy’s Laboratories Limited

[China Exclusive Distributor] Sino Universal Pharmaceutical Co., Ltd.